Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma

Abstract excerpt

The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroblastoma Research and Treatments
• Share to Sarcoma Diagnosis and Treatment
• Share to Signaling Pathways in Disease